Amorolfine

Amorolfine
	Above: molecular structure of amorolfine Below: 3D representation of an amorolfine molecule
Clinical data
Trade names	Loceryl, others
AHFS/Drugs.com	International Drug Names
ATC code	D01AE16 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) / Schedule 2;
Identifiers
	IUPAC name (±)-(2R,6S)-rel-2,6-Dimethyl-4-{2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl}morpholine;
CAS Number	78613-35-1;
PubChem CID	54260;
ChemSpider	49010;
UNII	AB0BHP2FH0;
KEGG	D02923;
ChEBI	CHEBI:599440;
ChEMBL	ChEMBL489411;
CompTox Dashboard (EPA)	DTXSID0046690 ;
Chemical and physical data
Formula	C21H35NO
Molar mass	317.517 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O2[C@@H](CN(CC(C)Cc1ccc(cc1)C(C)(C)CC)C[C@@H]2C)C;
	InChI InChI=1S/C21H35NO/c1-7-21(5,6)20-10-8-19(9-11-20)12-16(2)13-22-14-17(3)23-18(4)15-22/h8-11,16-18H,7,12-15H2,1-6H3/t16?,17-,18+; Key:MQHLMHIZUIDKOO-AYHJJNSGSA-N;

Amorolfine (or amorolfin), is a morpholine antifungal drug that inhibits Δ¹⁴-sterol reductase and cholestenol Δ-isomerase, which depletes ergosterol and causes ignosterol to accumulate in the fungal cytoplasmic cell membranes. Sold under the brand name Loceryl among others, amorolfine is commonly available in the form of a nail lacquer, containing 5% amorolfine hydrochloride as the active ingredient. It is used to treat onychomycosis (fungal infection of the toe- and fingernails). Amorolfine 5% nail lacquer in once-weekly or twice-weekly applications was shown in two decades-old studies to be between 60% and 71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment (after six months of treatment) were 38% and 46%. However, full experimental details of these trials were not available, and since they were first reported in 1992 there have been no subsequent trials.^[2]

It is a topical solution for the treatment of toenail infections.^[3]^[4] Systemic treatments may be considered more effective.^[2]

It is approved for sale over-the-counter in Australia, Brazil, Russia, Germany, and the UK.^{[citation needed]}

Notes

^ "Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025" (pdf). Therapeutic Goods Administration (TGA). May 2025. Retrieved 31 August 2025.
^ ^a ^b Williams HC (2003). Evidence-Based Dermatology. Blackwell. ISBN 978-1-4443-0017-8.
^ Flagothier C, Piérard-Franchimont C, Piérard GE (March 2005). "New insights into the effect of amorolfine nail lacquer". Mycoses. 48 (2): 91–4. doi:10.1111/j.1439-0507.2004.01090.x. hdl:2268/6502. PMID 15743424. S2CID 28403598.
^ Feng X, Xiong X, Ran Y (May 2017). "Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review". Dermatologic Therapy. 30 (3) e12457. doi:10.1111/dth.12457. PMID 28097731.

[1] "Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025" (pdf). Therapeutic Goods Administration (TGA). May 2025. Retrieved 31 August 2025.

[Williams-2] Williams HC (2003). Evidence-Based Dermatology. Blackwell. ISBN 978-1-4443-0017-8.

[pmid15743424-3] Flagothier C, Piérard-Franchimont C, Piérard GE (March 2005). "New insights into the effect of amorolfine nail lacquer". Mycoses. 48 (2): 91–4. doi:10.1111/j.1439-0507.2004.01090.x. hdl:2268/6502. PMID 15743424. S2CID 28403598.

[pmid28097731-4] Feng X, Xiong X, Ran Y (May 2017). "Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review". Dermatologic Therapy. 30 (3) e12457. doi:10.1111/dth.12457. PMID 28097731.

[1]

[2]

[3]

[4]